Compare Danaher Corporation (DHR) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Halliburton Company — how do they compare? Danaher Corporation trades at $217.43 (market cap $152.87B), while Halliburton Company trades at $32.44 (market cap $27.14B). The key difference: Danaher Corporation is far larger — about 5.6× Halliburton Company's market cap, and Halliburton Company pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Halliburton Company for 89 Days on average.
| DHR | HAL | |
|---|---|---|
Market Cap | $152.87B | $27.14B |
Volume | 5,228,698 | 11,258,156 |
Sector | Health | Energy |
52-Week High | $242.05 | $42.98 |
52-Week Low | $161.91 | $21.82 |
Typical Hold Time | 69 Days | 89 Days |
Enterprise Value | $175.08B | $33.29B |
Dividend Yield | 0.74% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
Halliburton (HAL) trades at $31.75, down 2.96% on the day, with technical indicators showing bearish momentum. The stock has demonstrated consistent earnings beats in recent quarters and maintains solid profitability metrics including 7.16% net margin and 14.89% ROE. Recent developments include expansion into Venezuela through partnerships with Eneva and WESCA, along with a major contract win for Cyprus' Cronos gas project, positioning the company for international growth opportunities.
Despite near-term technical weakness, Halliburton presents value with a 16.62 P/E ratio and strong analyst support (73% buy ratings) targeting $43.11 consensus. Risks include oil price volatility and execution challenges in new international markets, but the company's diversified service portfolio and improving cash flow trends support long-term growth prospects in the energy services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
